Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients
about
Chronic myeloid leukemia: reminiscences and dreamsCurrent status of hematopoietic stem cell transplant in chronic myeloid leukemiaThe achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.Chronic Myelogenous Leukemia, Version 1.2014Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemiaTreatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experienceLong-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalitiesPreclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target.Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects.Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.New Methodologies in the Molecular Monitoring of CML.Monitoring disease burden in chronic myeloid leukemia: Past, present, and future.Molecular monitoring of chronic myeloid leukemia: present and future.Deep molecular responses achieved in chronic myeloid leukemia in chronic phase patients with BCR-ABL1 >10% at 3 months who are early switched to nilotinib.Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications.Predictive parameters for imatinib failure in patients with chronic myeloid leukemia.Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects.
P2860
Q26748769-A3FC8BFE-1C4C-48C9-B12E-984F33975611Q27010475-31494E10-AA84-471F-973A-59D36CFE8017Q34163101-696511F7-DE84-4AC2-99DB-A5709B08F835Q34522810-16D6BF62-8305-4C1B-B0EE-84D9AD9C1281Q34639998-91DC6D65-DE48-42AA-BD05-3D0A2CA9E8E0Q34644820-A1C589BB-6617-4CD7-AA94-74731FA0D12DQ35899653-170D56CC-A89B-4DE6-951D-2E8276408EE0Q37025987-B2ECD978-E7B4-4BED-8C1C-CB811C4FA531Q37026032-6FC150DA-299D-4A04-8FA0-2A99266FBE10Q37095355-A8FDBFEC-BA67-4F3B-BE30-243BD79078BFQ37263168-AB439E6F-1264-4FE3-803D-523B0C54C37FQ37322437-5C8A7C49-94AB-41C9-92D6-25E6921A9CF8Q37579983-E3CA39B9-15DE-48BC-8F2D-F026C977E0CCQ38199143-E6858B05-42F1-4FCC-8C21-DBF119B2740BQ38762203-4B9AC66D-80F8-41AF-A853-846EA219C2E8Q38802249-7694DFC5-9C4E-416F-92A3-69E9D9052A67Q38828713-19619FE7-DF74-44E4-8A71-17053B9C453FQ41578421-CF8D316A-AAA1-4F74-BF47-C7A57C283566Q44394170-153B8C79-B4B0-4F2F-852A-03387C46694FQ47413364-A3545616-F88B-487B-A8CB-76CE97F82239Q50997822-A671F6B6-90EA-4911-BFD3-02F527198634Q54397703-3E5BC473-210F-4258-B2E9-71863008F637
P2860
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 December 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Responses to second-line tyros ...... onic myeloid leukemia patients
@en
Responses to second-line tyros ...... nic myeloid leukemia patients.
@nl
type
label
Responses to second-line tyros ...... onic myeloid leukemia patients
@en
Responses to second-line tyros ...... nic myeloid leukemia patients.
@nl
prefLabel
Responses to second-line tyros ...... onic myeloid leukemia patients
@en
Responses to second-line tyros ...... nic myeloid leukemia patients.
@nl
P2093
P2860
P1433
P1476
Responses to second-line tyros ...... onic myeloid leukemia patients
@en
P2093
Alistair Reid
Amr R Ibrahim
David Marin
Dragana Milojkovic
Jane F Apperley
John Goldman
Katayoun Rezvani
Letizia Foroni
P2860
P304
P356
10.1182/BLOOD-2011-10-383000
P407
P577
2011-12-14T00:00:00Z